Press Release Archive

(BUSINESS WIRE)--Private practice isn’t for everyone, but for graduating veterinary students facing an average of $120,000 in debt, it often is the only logical choice. A new program—the Pfizer Animal Health–Morris Animal Foundation (MAF) Veterinary Fellowship for Advanced Study—gives current practitioners necessary financial support while they pursue a veterinary research career. The program commits a minimum of nearly $1.7

(BUSINESS WIRE)--The Corporate Council on Africa (CCA) announced today that Pfizer Inc will sponsor the 7th Biennial U.S. – Africa Business Summit: Realizing the Investment Power of Africa, to be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 1, 2009. At a Pfizer-sponsored workshop titled Mobilizing Resources for Strengthening African Health Systems: A Case Study of Pfizer

(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation. The site will be the first to focus on patient privacy rights to connect patients,

(BUSINESS WIRE)--Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was conducted during Nigeria’s worst meningitis epidemic in history. Under the terms of the settlement, Kano State will dismiss both the civil and criminal Trovan-related cases it filed against the company and various individuals, and Pfizer

(BUSINESS WIRE)--Pfizer today announced a partnership with Fudan University to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree program, a first of its kind in China, is designed to develop qualified professionals to support clinical research which is rapidly increasing in China. “Pfizer is committed to creating and expanding our partnerships in China,

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the BMO Capital Markets 9th Annual Focus On Healthcare Conference on Wednesday, August 5, 2009 at 9:00 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “BMO Capital Markets Healthcare Conference

(BUSINESS WIRE)--At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® (zidovudine/lamivudine) experienced comparable virologic suppression to undetectable levels and significantly greater increases in CD4 T-cell count through 96-weeks, compared to patients taking efavirenz in combination with zidovudine/ lamivudine. The data

(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer’s disease.1,2 Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation Inc., is in

(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties. “We are excited about the potential